Vera Therapeutics
VERA
76 hedge funds and large institutions have $612M invested in Vera Therapeutics in 2023 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 31 increasing their positions, 20 reducing their positions, and 13 closing their positions.
133% more funds holding in top 10
Funds holding in top 10: 3 → 7 (+4)
111% more capital invested
Capital invested by funds: $290M → $612M (+$322M)
55% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 20
46% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 13
9% more funds holding
Funds holding: 70 → 76 (+6)
2.92% less ownership
Funds ownership: 89.07% → 86.14% (-2.9%)
44% less call options, than puts
Call options by funds: $2.1M | Put options by funds: $3.73M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
+$23.7M |
| 2 |
Morgan Stanley
New York
|
+$8.38M |
| 3 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$8.3M |
| 4 |
BlackRock
New York
|
+$6.86M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$14M |
| 2 |
DM
Deerfield Management
New York
|
-$10.1M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.05M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$7.01M |
| 5 |
OCA
Octagon Capital Advisors
New York
|
-$6.55M |
VERA Hedge Fund Activity: Q2 2023 in Review
76 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Vera Therapeutics (VERA) for Q2 2023, worth a combined $612M — up 111% from $290M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new VERA positions and 13 closed out — a net gain of 6 holders — while 31 added to existing stakes and 20 trimmed.
The largest buyer was Commodore Capital, adding an estimated $23.7M. The largest seller was Millennium Management, cutting an estimated $14M.
- 76 institutional investors held Vera Therapeutics (VERA) as of Q2 2023, up from 70 in Q1 2023.
- Funds reported $612M of Vera Therapeutics stock for Q2 2023, up 111% quarter-over-quarter.
- 19 funds opened new Vera Therapeutics positions in Q2 2023 and 13 closed out, a net change of +6 holders.
- The largest Vera Therapeutics buyer in Q2 2023 was Commodore Capital, an estimated $23.7M added.
- The largest Vera Therapeutics seller in Q2 2023 was Millennium Management, an estimated $14M sold.
Based on aggregated 13F filings for Q2 2023.